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Abstract Hyperuricemia is a frequent complication of chron-
ic kidney disease (CKD). Febuxostat is a novel xanthine
oxidase inhibitor that is metabolized by many metabolic path-
ways in the kidney and the liver. We performed a 1-year
cohort study of 73 hyperuricemic patients who had an esti-
mated glomerular filtration rate (eGFR) below 45 ml/min and
were being treated with urate-lowering therapy. In 51 patients,
treatment was changed from allopurinol to febuxostat, and the
other 22 patients were continued on allopurinol. The serum
levels of uric acid (UA) level, creatinine, and other biochem-
ical parameters were measured at baseline and after 3, 6, 9,
and 12 months of treatment. The serum UA levels significant-
ly decreased from 6.1±1.0 to 5.7±1.2 mg/dl in the febuxostat
group and significantly increased from 6.2±1.1 to 6.6±
1.1 mg/dl in the allopurinol group. The eGFR decreased
27.3 to 25.7 ml/min in the febuxostat group and from 26.1
to 19.9 ml/min in the allopurinol group. The switch from
allopurinol to febuxostat was significantly associated with
the changes in eGFR according to a multiple regression anal-
ysis (β=−0.22145, P<0.05). Febuxostat reduced the serum
UA levels and slowed the progression of renal disease in our
CKD cohort in comparison with allopurinol.
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Introduction
Hyperuricemia is a frequent complication of chronic kidney
disease (CKD) and with other risk factors for CKD, such as
hypertension and metabolic syndrome [1]. Uric acid (UA) is
the end product of purine metabolism in humans, and approx-
imately 70 % of UA is eliminated by urinary excretion.
Because urinary UA excretion is decreased in CKD patients,
the prevalence of hyperuricemia is higher [2]. However, hy-
peruricemia has not been considered to have a causal role in
CKD [3]. Evidence that hyperuricemia is an independent risk
factor for CKD has been increasing in the past few years [4].
In an epidemiologic study of a healthy population of 21,475
subjects who were followed for 7 years, hyperuricemia was
found to independently increase the risk of new onset
CKD [5].
CKD is associated with strongly and consistently with
cardiovascular disease (CVD) and mortality [6]. The mecha-
nism through which UA is regulated by the kidney and the
relationship between UA, kidney function, and CVD are not
fully understood [7]. Recently, evidence has accumulated
showing that hyperuricemia has a role in the pathogenesis of
CVD and the progression of CKD, indicating the necessity for
treatment even in the absence of symptoms of gouty arthritis
[8, 9]. However, a major challenge in treating patients with
hyperuricemia is the occurrence of drug-related adverse ef-
fects that are often augmented in the presence of kidney
dysfunction [10].
Pharmacologic options for urate-lowering therapy consist
of urate synthesis inhibitors and uricosuric agents. Most uri-
cosuric agents are not indicated for patients with CKD be-
cause of their mechanism of action; hyperuricemia in CKD
patients is mainly treated with xanthine oxidase (XO)
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inhibitors [11]. Allopurinol is metabolized by aldehyde oxi-
dase to oxypurinol, which is also a XO inhibitor. Oxypurinol
is then excreted via the kidney; its efficacy is insufficient, and
the risk of adverse events is higher in some CKD patients [12].
Febuxostat is a novel XO inhibitor that became available
clinically in 2011 in Japan, and it is metabolized by many
metabolic pathways in the kidney and the liver.
The aim of this study was to evaluate the effects of
switching the treatment of hyperuricemic patients with CKD
from allopurinol to febuxostat on the serum UA levels and the
progression of their renal disease.
Methods
Patients
We performed a 1-year retrospective observational study of 73
hyperuricemic patients who had an estimated glomerular fil-
tration rate (eGFR) below 45 ml/min and were being treated
with urate-lowering therapy. The criteria for inclusion as
subjects of this study were the following: (1) presence of
CKD as manifested by an eGFR below 45 ml/min, (2) current
urate-lowering therapy with allopurinol, (3) stable renal func-
tion (no increase in baseline serum creatinine by 50 % in the
previous 3 months), and (4) stable clinical condition (no
hospitalization in the previous 3 months).
A total of 85 patients in our renal clinic had an eGFR
<45 ml/min and were being treated with allopurinol at the
time of entry. One patient had been hospitalized within
3 months before start of this study. Febuxostat was prescribed
for 57 patients of the remaining 84 patients, and they consti-
tuted the febuxostat group. The other 27 patients continued to
be treated with allopurinol and constituted the allopurinol
group. Three nephrologists decided on the switch from allo-
purinol to febuxostat and the dose of prescription in consid-
eration of serum UA levels, renal function, and requirements
of the patients. All of the subjects in the febuxostat group
began the treatment with febuxostat between April 2012 and
December 2012.
The baseline demographic data, laboratory data, and infor-
mation concerning comorbid conditions and medication were
collected at the time of entry, and serum levels of UA and
creatinine were measured 3, 6, 9, and 12 months after the start
of the study. The eGFR was calculated using a formula based
on serum creatinine (Cr) developed by the Japanese Society of
Nephrology for the Japanese population [eGFR (ml/min/
1.73 m2)=194×Cr−1.094×age−0.287 (×0.739 if women) [13].
The study was performed in accordance with the Declaration
of Helsinki and the Principles of Good Clinical Practice. The
Institutional Research Ethics Committee approved the study
protocol (No. 1841).
Endpoints
The primary endpoint of interest was serum UA levels after
1 year from the switch from allopurinol to febuxostat. The
secondary endpoint was the changes in eGFR in the
febuxostat group and allopurinol group.
Statistical analysis
Continuous variables are reported as the mean±SD, and cat-
egorical variables are reported as percentages unless otherwise
stated. Non-paired two-tailed Student’s t tests were used to
compare continuous variables between the febuxostat group
and allopurinol group. Paired two-tailed Student’s t tests were
used to compare pre-treatment and post-treatment values.
Multiple regression analysis was performed by making eGFR
the dependent variable to estimate the effect of the switch from
allopurinol to febuxostat on eGFR. P values less than 0.05
were considered to indicate statistical significance. All analy-
ses were performed with the JMP for Windows software
program (SAS Institute, Cary, NC, USA).
Results
Eighty-four patients were enrolled in the study. This was a
retrospective observational cohort study. Treatment of 57
patients was switched from allopurinol to febuxostat, and the
other 27 patients were continued on allopurinol. During the 1-
year observation period, five patients (8.8 %) in the febuxostat
group and four patients (14.8 %) in the allopurinol group
developed indications for hemodialysis. One patient in the
febuxostat group was transferred to a different renal clinic,
and one patient in the allopurinol group died a sudden death;
both patients were excluded from the study for comparison of
the changes in renal function.
The baseline characteristics, including laboratory data, of
the both groups are shown in Table 1. There were no signif-
icant differences in clinical parameters in the febuxostat group
and allopurinol group, but the mean age of the patients in the
febuxostat group tended to be lower, and they had lower
percentages of nephrosclerosis and diabetic nephropathy as
an etiology of CKD.
Changes in serum UA level of each drug group
The changes in serum UA levels in each group between
3 months before and 12 months after the time of entry are
shown in Table 2. The difference between the serum UA
levels in the two groups before the start of the study was not
significant. The serum UA levels had significantly decreased
after 9 months in the febuxostat group but had significantly
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increased after 12 months in the allopurinol group, and as a
result, the serum UA level in the febuxostat group was signif-
icantly lower than in the allopurinol group at 9 months after
switching the drug. There was no significant difference in the
rate of achievement of the target serum UA level (<6.0 mg/dl)
between the two groups at the start of this study (45.1 % in the
febuxostat group vs 50 % in the allopurinol group, P=0.70),
but after 1-year of treatment, in this study, the achievement
rate was significantly higher in the febuxostat group than in
the allopurinol group (68.6 % vs 31.8 %, P<0.01).
Changes in serum UA level of each drug dosage
Figure 1 shows the changes in serum UA levels during the
observation period in the patient group. Two patients whose
dose had changed after switching to febuxostat, one patient
who had been switched from allopurinol 200 mg/day to
febuxostat 10 mg/day, one patient who had been switched
from allopurinol 200 mg/day to febuxostat 40 mg/day, and
three patients who were switched to combination therapy were
excluded in this figure. These results show that the 1000-mg
dose of allopurinol and the 10-mg dose of febuxostat have
essentially equivalent effect. On the other hand, the switch
from allopurinol 200 mg/day to febuxostat 20mg/day resulted
in an increase serum UA level.
Progression of renal disease
The changes in eGFR in the two groups between 3 months
before and 12 months after the time of entry are shown in
Table 3. There was no significant difference in the eGFR
values of the two groups before 3 months and at the start of
this study. After 9 months, the eGFR had decreased in both
groups but had decreased more in the allopurinol group, and
as a result, the eGFRwas significantly higher in the febuxostat
group than in the allopurinol group after 1-year treatment. In
the febuxostat group, 12 (23 %) patients increased eGFR, but
in the allopurinol group, there was no patient that increased
eGFR. The results of a multiple regression analysis that in-
cluded age, gender, hemoglobin, albumin, eGFR, prevalence
of diabetes, use of renin-angiotensin-aldosterone blockers,
and the switch from allopurinol to febuxostat showed that
treatment with febuxostat independently associated with the
change in eGFR (β=0.22145, P<0.05, Table. 4).
Adverse events
Liver function abnormality (elevation of transaminase) was
observed in one patient of febuxostat group, and a mild attack
of gout was observed in one patient during 3 months after the
time of entry in the febuxostat group. However, both adverse
events were soon resolved, and treatment was not
discontinued because of improvement in both groups.
Discussion
Hyperuricemia is a frequent complication of CKD but also is a
risk factor for CVD, and CKD is considered a very important
risk factor for CVD [7]. Consequently, it is very difficult to
independently evaluate the effect of hyperuricemia on the
progression of CKD, the risk of CVD, and mortality
[14–16]. Recent epidemiologic studies indicated that UA






Age (years) 67.4±12.3 72.9±10.7
Gender (M:F) 29:22 16:6
Body weight (kg) 58.0±13.3 59.3±9.8
Hemoglobin (g/dl) 11.9±1.8 11.5±1.9
Serum albumin (g/dl) 4.0±0.5 3.8±0.4
Serum creatinine (mg/dl) 2.2±1.1 2.1±0.7
eGFR (ml/min per 1.73 m2) 27.2±10.5 26.2±9.2
Uric acid (mg/dl) 6.1±0.9 6.2±1.1
Etiology of renal disease (%)




RAAS blockers (%) 77 86
Variables are presented as mean±SD
No significant differences were observed between the two groups
RAAS renin-angiotensin-aldosterone system







Before 3 months 6.2±0.9 6.4±0.7 NS
Basal 6.1±1.0 6.2±1.1 NS
3 months 5.9±1.3 6.2±0.7 NS
6 months 5.8±1.2 6.3±1.0 NS
9 months 5.7±1.3* 6.4±1.0 <0.05
12 months 5.7±1.2* 6.6±1.1* <0.01
Variables are presented as mean±SD
*significant differences (P<0.05) in comparison to baseline period wtihin
each group
**difference in comparison to each group within same period
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had a causal role in the progression of renal disease in hyper-
tensive women [17], a normotensive population [18], and
diabetic patients [19]. A large epidemiologic study of
177,570 individuals for a total of 527,597 person-years re-
vealed that a higher serum UA level was an independent risk
factor for end-stage renal disease (HR 2.14 [1.65–2.77] for
highest vs lowest quartile) [20].
Several mechanisms have been postulated for the causal role
of UA in the progression of renal disease. One of the postulated
mechanism is that hyperuricemia induces endothelial dysfunc-
tion because of a reduction in nitric oxide. The serum nitric
oxide level decreases when hyperuricemia is induced in rats,
and the decrease is reversed after administration of allopurinol
[21]. Another postulated mechanism is that hyperuricemia
stimulates the renin-angiotensin system and proliferation of
vascular smooth muscle cells (VSMCs) [22]. Incubation of
rat VSMCs with UA stimulated the proliferation of VSMC
and increased anigiotensinogen messenger RNA expression,
and both responses were prevented by losartan and captopril.
Several studies in the past few years have evaluated the
effect of urate-lowering therapy on renal function. A random-
ized control trial conducted on 113 patients with an eGFR
<60 ml/min showed that allopurinol decreased the serum UA
level and had a renoprotective effect [23]. After 24 months in
the control group, the eGFR had decreased from 39.5 to
35.9 ml/min but increased from 40.8 to 42.2 ml/min in the
allopurinol group. The serum C-reactive protein level and
prevalence of CVD decreased in the allopurinol group. Siu
et al. also reported observing a renoprotective effect of allo-
purinol after 1 year of treatment in a randomized control trial
conducted on 54 patients with a serum creatinine level above
1.35 mg/d1 [24].
Fig. 1 Changes in serum UA
levels in the each drug dosage
group. Values are expressed as
mean values







Before 3 months 29.3±11.5 25.9±8.9 NS
Basal 27.3±10.6 26.1±9.2 NS
3 months 26.4±10.5 24.2±9.4 NS
6 months 26.0±10.4* 23.3±9.4* NS
9 months 25.9±11.0* 22.0±9.2* NS
12 months 25.7±11.3* 19.9±9.5* <0.05
Variables are presented as mean±SD
*significant differences (P<0.05) in comparison with baseline period
within each group
**difference in comparison to each group within same period
Table 4 Multiple regression analysis for detecting independent variables
associated with the changes in eGFR
β value P value
Age (years) −0.06799 0.4952
Gender (M) 0.13059 0.2027
Hemoglobin (g/dl) 0.079493 0.5471
Serum albumin (g/dl) −0.04083 0.717
eGFR (ml/min per 1.73 m2) 0.453673 0.0004
Diabetes nephropathy −0.02244 0.8286
RAAS blockers (%) 0.154734 0.1261
Switch to febuxostat 0.22145 0.0375
R2=0.4245 in this model
RAAS renin-angiotensin-aldosterone system
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Allopurinol has long been regarded as the only XO inhibitor
drug, but allopurinol is metabolized in the kidney; the dosage
must be reduced in patients with CKD. By contrast, since
febuxostat is metabolized by more than one metabolic pathway
in the kidney and liver, it is not necessary to reduce the dosage
in patents with CKD [25]. Sakai et al. have recently reported
that febuxostat is effective for treating allopurinol-resistant
hyperuricemia in CKD patients [26]. Whereas the eGFR slope
was negative during allopurinol treatment, it became positive
after the switch to febuxostat. The efficacy and tolerability of
the switch from allopurinol to febuxostat in patients with
moderate CKD in this study have demonstrated useful infor-
mation for clinical practice in renal clinic. On the other hand,
Stamp et al. showed the efficacy and safety of increasing the
allopurinol dose above the recommendation dose of creatinine
clearance-based dosing guidelines in CKD patients with a
mean creatinine clearance 62.2 ml/min [27]. Therefore, it is
important to compare the renoprotective effects of allopurinol
and febuxostat in a large cohort of CKD patients.
There were several limitations to the present study. The first
limitation was that this study was not a randomized trial.
However, there were no significant differences in baseline
characteristics between the two groups, and multiple regres-
sion analysis was performed by making eGFR the dependent
variable to estimate the effect of the switch from allopurinol to
febuxostat on eGFR. The second limitation was not having
evaluated urinary protein because there were missing values.
However, the difference between the serum albumin levels of
the two groups was not significant, and the multiple regression
analysis included serum albumin.
Conclusion
The switch from allopurinol to febuxostat reduced their serum
UA levels and slowed the progression of renal disease more
than in the group which allopurinol was continued in the
cohort of hyperuricemia patients with advanced CKD who
were treated with allopurinol. These results warrant future
trials of XO inhibitors including allopurinol and febuxostat
in hyperuricemic patients with advanced CKD.
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